Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia

Treatment Resistant Schizophrenia Clinical Trial

Official title: Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia: A Randomized, Group Sequential Adaptive Design, Controlled Clinical Trial

Status Recruiting

Clinical Trial Summary

Dextromethorphan acts as N-methyl-D-aspartate (NMDA) antagonist. In Treatment resistant schizophrenia(TRS) the efficacy of treatment response by clozapine is only around 40%. Numerous augmentation agent have been tried which includes antipsychotics, anticonvulsants, antidepressants and NMDA antagonist. The NMDA antagonist such as Riluzole and Memantine have shown good efficacy in TRS. Therefore we are evaluating NMDA antagonist, dextromethorphan in TRS. The dextromethorphan or placebo will be administered along with clozapine in TRS patients. The study is randomized double blind placebo controlled group sequential trial.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Schizophrenia
• Treatment Resistant Schizophrenia

• NCT number: NCT05944510
• Study type: Interventional
• Source: All India Institute of Medical Sciences, Bhubaneswar
• Contact: RITUPARNA MAITI, M.D.
• Phone: 9438884191
• Email: pharm_rituparna@aiimsbhubaneswar.edu.in
• Status: Recruiting
• Phase: Phase 4
• Start date: August 31, 2023
• Completion date: December 31, 2024